{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:54:54Z","timestamp":1790906094808,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004482","name":"Kuwait University","doi-asserted-by":"publisher","award":["PP02\/19"],"award-info":[{"award-number":["PP02\/19"]}],"id":[{"id":"10.13039\/501100004482","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejps.2026.107511","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:03:48Z","timestamp":1773763428000},"page":"107511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["In vivo antiseizure activity of triazolyl oxazolidinone derivatives in rats"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9582-3419","authenticated-orcid":false,"given":"Mohammad G.","family":"Qaddoumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen A.","family":"Hedaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhya","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser F.","family":"Al-Tannak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oludotun A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel B.","family":"Kombian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejps.2026.107511_bib0028","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2026.107511_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108884","article-title":"The novel dual-mechanism Kv7 potassium channel\/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-hz refractory seizure mouse model","volume":"203","author":"Bloms-Funke","year":"2022","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.ejps.2026.107511_bib0001","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neuroscience.2020.09.002","article-title":"Seizures alter cortical representations for complex movements","volume":"449","author":"Brown","year":"2020","journal-title":"Neuroscience"},{"issue":"23","key":"10.1016\/j.ejps.2026.107511_bib0026","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/0024-3205(85)90573-9","article-title":"Variation in threshold and pattern of electroshock-induced seizures in rats depending on site of stimulation","volume":"37","author":"Browning","year":"1985","journal-title":"Life Sci."},{"key":"10.1016\/j.ejps.2026.107511_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106991","article-title":"mTOR and HDAC2 are simultaneously activated during electrically induced kindling of seizures","volume":"185","author":"Chmielewska","year":"2022","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2026.107511_bib0039","first-page":"293","article-title":"Animal models of epilepsy and progressive effects of seizures","volume":"97","author":"Cortez","year":"2006","journal-title":"Adv. Neurol."},{"issue":"2","key":"10.1016\/j.ejps.2026.107511_bib0024","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jneumeth.2008.04.019","article-title":"The pilocarpine model of temporal lobe epilepsy","volume":"172","author":"Curia","year":"2008","journal-title":"J. Neurosci. Methods"},{"issue":"5","key":"10.1016\/j.ejps.2026.107511_bib0012","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.neuron.2023.01.013","article-title":"Glioma epileptiform activity and progression are driven by IGSF3-mediated potassium dysregulation","volume":"111","author":"Curry","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.ejps.2026.107511_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107087","article-title":"The effects of cannabidiol and Delta9-tetrahydrocannabinol, alone and in combination, in the maximal electroshock seizure model","volume":"190","author":"Dlugosz","year":"2023","journal-title":"Epilepsy Res."},{"issue":"5","key":"10.1016\/j.ejps.2026.107511_bib0019","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1039\/D2MD00415A","article-title":"Oxazolidinones as versatile scaffolds in medicinal chemistry","volume":"14","author":"Fernandes","year":"2023","journal-title":"RSC. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107511_bib0041","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2016.11.022","article-title":"Drug development for refractory epilepsy: the past 25 years and beyond","volume":"44","author":"Golyala","year":"2017","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.ejps.2026.107511_bib0006","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/fcp.12614","article-title":"Is the mechanism of action of antiseizure drugs a key element in the choice of treatment?","volume":"35","author":"Guery","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"194","key":"10.1016\/j.ejps.2026.107511_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ane.12014","article-title":"The impact of epilepsy on patients' lives","author":"Kerr","year":"2012","journal-title":"Acta Neurol. Scand. Suppl."},{"issue":"9","key":"10.1016\/j.ejps.2026.107511_bib0043","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41573-024-00981-w","article-title":"New epilepsy therapies in development","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.ejps.2026.107511_bib0013","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1528-1167.2012.03716.x","article-title":"Finding a better drug for epilepsy: antiepileptogenesis targets","volume":"53","author":"Kobow","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2026.107511_bib0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neuroscience.2011.01.062","article-title":"In vitro electrophysiological investigations of the acute effects of linezolid and novel oxazolidinones on central nervous system neurons","volume":"180","author":"Kombian","year":"2011","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.ejps.2026.107511_bib0021","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000346005","article-title":"Novel actions of oxazolidinones: in vitro screening of a triazolyloxazolidinone for anticonvulsant activity","volume":"22","author":"Kombian","year":"2013","journal-title":"Med. Princ. Pract."},{"issue":"10","key":"10.1016\/j.ejps.2026.107511_bib0007","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejps.2026.107511_bib0017","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.neuropharm.2006.11.001","article-title":"A pharmacophore derived phenytoin analogue with increased affinity for slow inactivated sodium channels exhibits a desired anticonvulsant profile","volume":"52","author":"Lenkowski","year":"2007","journal-title":"Neuropharmacology."},{"issue":"11","key":"10.1016\/j.ejps.2026.107511_bib0010","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41582-020-00419-y","article-title":"Drug-resistant epilepsy - time to target mechanisms","volume":"16","author":"Lerche","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"9","key":"10.1016\/j.ejps.2026.107511_bib0015","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond","volume":"35","author":"Loscher","year":"2021","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.ejps.2026.107511_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107934","article-title":"New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal?","volume":"229","author":"Loscher","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.ejps.2026.107511_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/cells12091233","article-title":"Animal models of drug-resistant epilepsy as tools for deciphering the cellular and molecular mechanisms of pharmacoresistance and discovering more effective treatments","volume":"12","author":"Loscher","year":"2023","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.ejps.2026.107511_bib0038","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrd4126","article-title":"New avenues for anti-epileptic drug discovery and development","volume":"12","author":"Loscher","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.ejps.2026.107511_bib0023","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0165-6147(00)01974-X","article-title":"Current status and future directions in the pharmacotherapy of epilepsy","volume":"23","author":"Loscher","year":"2002","journal-title":"Trends. Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2026.107511_bib0040","series-title":"Models of Seizures and Epilepsy","first-page":"111","article-title":"O.C. Pharmacologic models of generalized absence seizures in rodents","author":"MAaS","year":"2006"},{"key":"10.1016\/j.ejps.2026.107511_bib0027","series-title":"Models of Seizures and Epilepsy","first-page":"153","article-title":"Electrical stimulation-induced models of seizures","year":"2006"},{"issue":"6","key":"10.1016\/j.ejps.2026.107511_bib0002","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1007\/s00415-021-10949-0","article-title":"Frontal lobe seizures: overview and update","volume":"269","author":"McGonigal","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejps.2026.107511_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120766","article-title":"Drug-resistant epilepsy: definition, pathophysiology, and management","volume":"452","author":"Mesraoua","year":"2023","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.ejps.2026.107511_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900342","article-title":"Recent progress of 1,3,4-oxadiazoles as anticonvulsants: future horizons","volume":"353","author":"Nazar","year":"2020","journal-title":"Arch. Pharm. (Weinheim)"},{"issue":"3","key":"10.1016\/j.ejps.2026.107511_bib0037","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.yebeh.2012.08.014","article-title":"Interaction profile of Zizyphus jujuba with phenytoin, phenobarbitone, and carbamazepine in maximal electroshock-induced seizures in rats","volume":"25","author":"Pahuja","year":"2012","journal-title":"Epilepsy Behav."},{"issue":"10","key":"10.1016\/j.ejps.2026.107511_bib0032","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ardp.201100332","article-title":"Effects of varied substituents on the antibacterial activity of triazolylmethyl oxazolidinones","volume":"345","author":"Phillips","year":"2012","journal-title":"Arch Pharm"},{"key":"10.1016\/j.ejps.2026.107511_bib0033","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejmech.2013.05.041","article-title":"Synthesis and antibacterial activities of N-substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinones","volume":"66","author":"Phillips","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejps.2026.107511_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099770","article-title":"Evaluation of anticonvulsant actions of dibromophenyl enaminones using in vitro and in vivo seizure models","volume":"9","author":"Qaddoumi","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.ejps.2026.107511_bib0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejps.2019.01.011","article-title":"A novel oxazolidinone derivative PH192 demonstrates anticonvulsant activity in vivo in rats and mice","volume":"130","author":"Qaddoumi","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.ejps.2026.107511_bib0030","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0028-3908(90)90159-O","article-title":"Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats","volume":"29","author":"Rundfeldt","year":"1990","journal-title":"Neuropharmacology."},{"issue":"5","key":"10.1016\/j.ejps.2026.107511_bib0003","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1528-1167.2006.00971.x","article-title":"A comparison of self-reported quality of life between patients with epilepsy and neurocardiogenic syncope","volume":"48","author":"Santhouse","year":"2007","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.ejps.2026.107511_bib0014","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1684\/epd.2012.0512","article-title":"Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons","volume":"14","author":"Schmidt","year":"2012","journal-title":"Epileptic. Disord."},{"issue":"17","key":"10.1016\/j.ejps.2026.107511_bib0009","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.0000000000011839","article-title":"Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis","volume":"96","author":"Sultana","year":"2021","journal-title":"Neurology."},{"issue":"194","key":"10.1016\/j.ejps.2026.107511_bib0004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ane.12015","article-title":"Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients?","author":"Trinka","year":"2012","journal-title":"Acta Neurol. Scand. Suppl."},{"issue":"2","key":"10.1016\/j.ejps.2026.107511_bib0031","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1528-1157.1995.tb00978.x","article-title":"Effects of MK-801 and phenytoin on flurothyl-induced seizures during development","volume":"36","author":"Velisek","year":"1995","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ejps.2026.107511_bib0025","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.neuroscience.2008.02.066","article-title":"Kainate receptors in epilepsy and excitotoxicity","volume":"158","author":"Vincent","year":"2009","journal-title":"Neuroscience"},{"issue":"19","key":"10.1016\/j.ejps.2026.107511_bib0011","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1016\/j.neuron.2022.07.020","article-title":"Enhanced excitability of the hippocampal CA2 region and its contribution to seizure activity in a mouse model of temporal lobe epilepsy","volume":"110","author":"Whitebirch","year":"2022","journal-title":"Neuron"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T11:49:42Z","timestamp":1779709782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726000850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"alternative-id":["S0928098726000850"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107511","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo antiseizure activity of triazolyl oxazolidinone derivatives in rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107511"}}